Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.

Iftekhar Khan

Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.

Population & Patient Health

Research output: Contribution to journal › Article › peer-review

45 Citations (Scopus)

Original language	English
Journal	Journal of medical economics
Publication status	Published - 23 Feb 2012

Cite this

@article{327341fee4854d0bba8eba84b99eb6a8,

title = "Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.",

author = "Iftekhar Khan",

year = "2012",

month = feb,

day = "23",

language = "English",

journal = "Journal of medical economics",

issn = "1369-6998",

publisher = "Taylor & Francis",

}

TY - JOUR

T1 - Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.

AU - Khan, Iftekhar

PY - 2012/2/23

Y1 - 2012/2/23

M3 - Article

SN - 1369-6998

JO - Journal of medical economics

JF - Journal of medical economics

ER -